James D Kellner
Overview
Explore the profile of James D Kellner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
94
Citations
1571
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang Y, Knoll M, Herbert C, Bennett J, Feikin D, Garcia Quesada M, et al.
J Infect
. 2025 Jan;
90(3):106426.
PMID: 39864526
Background: Pneumococcal conjugate vaccines (PCVs) introduced in childhood national immunization programs lowered vaccine-type invasive pneumococcal disease (IPD), but replacement with non-vaccine-types persisted throughout the PCV10/13 follow-up period. We assessed PCV10/13...
2.
Garcia Quesada M, Peterson M, Bennett J, Hayford K, Zeger S, Yang Y, et al.
Lancet Infect Dis
. 2024 Dec;
PMID: 39706205
Background: Widespread use of pneumococcal conjugate vaccines (PCVs) has reduced vaccine-type invasive pneumococcal disease (IPD). We describe the serotype distribution of IPD after extensive use of ten-valent PCV (PCV10; Synflorix,...
3.
Robinson J, Kellner J, Crotts J, Travassos G, Chen G, Kirk V, et al.
PLoS One
. 2024 Dec;
19(12):e0311201.
PMID: 39661638
Background: The diagnosis of pediatric pneumonia and determination of the likely pathogen are complicated as the clinical picture overlaps with other respiratory illnesses, interpretation of radiographs is subjective, and laboratory...
4.
Soe P, Vanderkooi O, Sadarangani M, Naus M, Muller M, Kellner J, et al.
Lancet Reg Health Am
. 2024 Dec;
40:100949.
PMID: 39659558
Background: The Canadian National Vaccine Safety Network conducted active safety surveillance for COVID-19 vaccines. This study aimed to characterize the short-to-medium term safety of mRNA COVID-19 vaccines across the pediatric...
5.
Top K, Shulha H, Muller M, Valiquette L, Vanderkooi O, Kellner J, et al.
Vaccine
. 2024 Oct;
42(26):126445.
PMID: 39413493
Introduction: The Canadian National Vaccine Safety Network (CANVAS) conducted active participant-based surveillance for adverse events following immunization during the COVID-19 vaccine campaign. This study evaluated the association between COVID-19 vaccination...
6.
Soe P, Sadarangani M, Naus M, Muller M, Vanderkooi O, Kellner J, et al.
Front Public Health
. 2024 Aug;
12:1385426.
PMID: 39188790
Background: The Canadian National Vaccine Safety (CANVAS) network conducted a multi-center, prospective vaccine safety study to collect safety data after dose 1 and 2 of COVID-19 vaccines and follow up...
7.
Ricketson L, Doucette E, Alatorre I, Tarannum T, Gray J, Booth W, et al.
BMC Infect Dis
. 2024 Jul;
24(1):705.
PMID: 39026179
Background: There are few reports of longitudinal serologic responses in children following Sars-CoV-2 infection and vaccination. This study describes longitudinal SARS-CoV-2 antibody responses following infection, vaccination, or both (hybrid immunity)...
8.
Doucette E, Pateman M, Fullerton M, Lip A, Houle S, Kellner J, et al.
Front Public Health
. 2024 Jul;
12:1408871.
PMID: 39022406
Background: Vaccine hesitancy is a significant threat to public health. Healthcare providers (HCPs) can address hesitancy during routine patient conversations; however, few multidisciplinary education tools exist for HCPs to learn...
9.
MacDonald S, Dhungana M, Stagg V, McDonald S, McNeil D, Kellner J, et al.
Arch Public Health
. 2024 Jun;
82(1):89.
PMID: 38886808
Background: Maternal depression and anxiety can have a detrimental impact on birth outcomes and healthy child development; there is limited knowledge on its influence on immunization schedule adherence. Therefore, the...
10.
Doucette E, Ricketson L, Tarannum T, Alatorre I, Gray J, Constantinescu C, et al.
Paediatr Child Health
. 2024 Jun;
29(3):150-157.
PMID: 38827369
Objectives: Beginning early in the pandemic, there was a worldwide effort to develop effective vaccines against the SARS-CoV-2 virus. Before and after the approval and implementation of vaccines, there were...